Company Name MicuRx Pharmaceuticals
Mailing Address 3916 Trust Way Hayward, CA 94545
Company Description MicuRx is discovering and developing next-generation antibacterial andantifungal products. By making specific modifications to validatedantibiotics, MicuRx intends to improve overall pharmacological propertiesof antimicrobial drugs in order to overcome antibiotic resistance, increasethe antibacterial spectrum, improve the dosing regimen, or reduce adverseside effects.
Proceeds Purposes Proceeds from the Series B financing will be used to fund the U.S. development of MRX-I, a novel oral oxazolidinone antibiotic targeting infections due to multi-drug resistant Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE).